Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000671976 | SCV000797025 | likely pathogenic | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2018-01-10 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001068679 | SCV001233804 | pathogenic | not provided | 2022-08-09 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 556037). This variant has not been reported in the literature in individuals affected with USH2A-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Phe129Leufs*16) in the USH2A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in USH2A are known to be pathogenic (PMID: 10729113, 10909849, 20507924, 25649381). |
Blueprint Genetics | RCV001075571 | SCV001241198 | likely pathogenic | Retinal dystrophy | 2019-01-09 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000671976 | SCV002782935 | likely pathogenic | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2022-02-24 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003453337 | SCV004182984 | likely pathogenic | Retinitis pigmentosa 39 | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003453336 | SCV004182985 | likely pathogenic | Usher syndrome type 2A | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003453337 | SCV004208194 | likely pathogenic | Retinitis pigmentosa 39 | 2023-10-10 | criteria provided, single submitter | clinical testing |